Advances in polymeric and non-polymeric nanocarriers for the magnified delivery of levofloxacin against bacterial infection
Abstract
Abstract This review examines the latest developments in nanoscopic antibiotic formulations used to treat infections caused by bacteria. A wide range of nanocarrier platforms are discussed, including polymer-based nanoparticles (NPs), lipid-based vesicles, mesoporous silica, and other inorganic materials. The antibiotic levofloxacin (LVF) is predominantly used as a model drug given its broad-spectrum activity. Studies in this regard have evaluated drug loading and encapsulation efficiency (EE) using analytical techniques such as FTIR, DLS, and TEM. In vitro release kinetics was characterized through dialysis and fluorescence-based assays. Zone of inhibition and viability studies provided insights into antibacterial efficacy. Some approaches incorporated stimuli-responsive polymers or targeting ligands to facilitate controlled or targeted drug release. Overall, the nanocarriers demonstrated potential for sustained antibiotic levels, reduced dosing, and improved treatment of biofilms and intracellular infections compared to free drug administration. The review offers a comprehensive analysis of this promising field with implications for combating antibiotic resistance.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.